As observed in other inflammatory conditions, acute inflammation and low iron availability may also cause the suppression of EPO production and bone marrow hyporesponsiveness [25,26,27]; interestingly, Hanson AL et al. have recently shown how EPO production may vary in response to SARS-CoV-2 infection and the development of COVID-19 [29]. This evidence concerns the gene EPO and COVID-19.